GlassScriptPhysician profile
Sara Danielle Azzam
NPI 1932543717
$19,149.66
in general payments reported to CMS, 2019-2025
43 companies · $3,512 in 2025
The $3,512 reported for 2025 was more than what 79% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,409 · 2020: $429 · 2021: $2,126 · 2022: $3,693 · 2023: $3,467 · 2024: $3,513 · 2025: $3,512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,318.63 |
| Consulting Fee | $173.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,831.41 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Genentech USA, INC. | $2,584.67 | 2019-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $1,562.51 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,455.46 | 2019-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Genzyme Corporation | $1,358.84 | 2019-2025 | |
| Csl Behring | $1,236.74 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Novartis Pharmaceuticals Corporation | $950.79 | 2019-2025 | |
| Abbvie INC. | $686.38 | 2022-2024 | |
| Pfizer INC. | $638.96 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $520.41 | 2020-2025 | Takhzyro, Eohilia, Hyqvia |
| Hospira, INC. | $481.80 | 2023-2025 | |
| Pharming Healthcare, INC. | $460.54 | 2019-2025 | Ruconest |
| Amgen INC. | $449.80 | 2019-2025 | Tezspire |
| Grifols USA, LLC | $344.90 | 2019-2025 | Xembify |
| Biocryst US Sales Co., LLC | $290.50 | 2021-2024 | Orladeyo |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Azzam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.